Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26957555.
- Also identified by DOI 10.1158/1078-0432.CCR-16-0038 and PMC identifier 4946572.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The PI3K pathway is often aberrantly activated in estrogen receptor positive (ER(+)) breast cancer and therapies combining PI3K inhibitors and antiestrogens are under clinical development. Given that many PI3K inhibitors have substantial toxicities with continuous dosing and that alternate dosing schedules are equally active, further clinical exploration is warranted. Clin Cancer Res; 22(9); 2099-101. ©2016 AACRSee related article by Yang et al., p. 2250.
Medical subject headings
- Antineoplastic Agents
- Breast Neoplasms
- Phosphoinositide-3 Kinase Inhibitors
- Protein Kinase Inhibitors